insights_auto
Why is AGIO down 4,03%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
27,60 $
arrow_downward
-4,03%(-1,16) 1D
27,60 $
0,00% (0,00)
bedtimeAfter hours
Closed: 20 նոյ, 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
28,01 $
High
29,14 $
Low
27,43 $
Mkt. cap
1,65 մլրդ
Avg. vol.
1,13 մլն
Volume
776,20 հզր
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 մլն
No. of employees
540
Open
28,01 $
High
29,14 $
Low
27,43 $
Mkt. cap
1,65 մլրդ
Avg. vol.
1,13 մլն
Volume
776,20 հզր
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 մլն
No. of employees
540
News stories
From web sources and news partners
TradingView
·
2 ժամ առաջ
Stock Market Crash: Nasdaq, S&P 500 Suffer Worst Weekly Losses in Years
Traders Union
·
7 ժամ առաջ
VIX fear index hits highest level since April 2025 as S&P 500 plunges
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc